Galapagos NV (Euronext: GLPG) announced today that the Company will present data on the pharmacodynamics and efficacy of its selective JAK1 inhibitor GLPG0634 at the ACR (American College of Rheumatology) which will take place from 25-30 October 2013 in San Diego, CA, US. The abstracts are now available online on the ACR website.
Help employers find you! Check out all the jobs and post your resume.
